GNSC 001
Alternative Names: AAVIL-1Ra; GNSC-001; IL-1Ra; Sc-rAAV2.5IL-1RaLatest Information Update: 21 Jul 2025
At a glance
- Originator Mayo Clinic
 - Class Antirheumatics; Gene therapies
 - Mechanism of Action Gene transference; Interleukin 1 receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 
Highest Development Phases
- Phase I Osteoarthritis
 
Most Recent Events
- 16 Jul 2025 GNSC 001 receives Regenerative Medicine Advanced Therapy (RMAT) status for Osteoarthritis in USA
 - 11 Jun 2025 Updated adverse events and pharmacodynamics data from the phase Ib DONATELLO trial in Osteoarthritis presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR-2025)
 - 12 May 2025 GNSC 001 is still in phase-I development in Osteoarthritis(In the elderly, In adults) in USA (Intra-articular, Injection) (NCT05835895)